logo-loader
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals unveils new senior appointment

Andrew Wright, meanwhile, is coming in as financial controller and company secretary

1541404713_rsz_shutterstock_178464512.jpg
Chief operating officer Lawrence Pemble is leaving

HemoGenyx Pharmaceuticals PLC (LONHEMO) said that its chief operating officer is leaving as it unveiled a new senior appointment.

Lawrence Pemble is exiting immediately. Andrew Wright, meanwhile, is coming in as financial controller and company secretary, a “non-board position”.

Wright is a trained accountant who is currently the director of corporate development for Thomas Murray, a post-trade capital markets data and advisory firm and is an executive director of Trayned Insight, a data science company serving the healthcare and pharmaceutical industries.

Hemogenyx chief executive, Dr Vladislav Sandler, said: "I am delighted to welcome Andrew to the team and look forward to his support as we continue to advance the development of our novel therapeutic products for patients with blood and severe autoimmune diseases.

“I would also like to extend my thanks to Lawrence for his contribution to the board and we wish him well in his next ventures."

The company is developing technology that could transform bone marrow transplantation and the treatment of blood diseases.

Quick facts: HemoGenyx Pharmaceuticals

Price: 1.91 GBX

LSE:HEMO
Market: LSE
Market Cap: £6.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read